RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📢 Greenwich LifeSciences (Nasdaq: GLSI) to Host Investor Webinar on Advancing Breast Cancer Immunotherapy Greenwich LifeSciences, Inc. invites investors to a live webinar on Tuesday, April 29 at 4:15 PM EST to discuss the ongoing development of GLSI-100, an immunotherapy designed to reduce breast cancer recurrence in HER2/neu-positive patients. 💡 Why Investors Should Tune In: 🔬 Promising Phase IIb Results: Over 80% reduction in recurrence among HER2 3+ patients after 5 years of follow-up, with no serious adverse events reported. 🧪 Phase III Trial in Progress: The global FLAMINGO-01 study spans 150 clinical sites across the U.S. and Europe in collaboration with leading oncology research networks. 📊 Significant Market Opportunity: HER2-positive breast cancer affects hundreds of thousands of patients annually in the U.S. and EU. GLSI-100 targets patients who may not fully benefit from existing therapies like Herceptin or Kadcyla. 🎯 Gain insights into Greenwich LifeSciences, Inc.'s clinical strategy and upcoming milestones. 🔗 https://lnkd.in/efUguQhq Biotechnology Biotechnology News Breast Cancer Now #GLSI #BreastCancer #BiotechStocks #ClinicalTrials #HER2 #Immunotherapy #InvestorWebinar #OncologyInvesting 

🚀 bioAffinity Technologies (Nasdaq: BIAF): Major Efficiency Gains for CyPath Lung Test! bioAffinity Technologies has significantly enhanced the efficiency of its CyPath® Lung diagnostic, a noninvasive test for early lung cancer detection. Key updates include: ✅ 50% Faster Data Acquisition ✅ 60% Lower Sample Processing Costs ✅ 25%+ Decrease in Per-Test Cost ✅ No Changes to Patient Experience or Test Accuracy (92% sensitivity, 87% specificity) 🧪 These improvements boost lab throughput by over 10%, reduce reagent use, and preserve test performance—strengthening CyPath Lung’s position as a cost-effective and scalable solution in the fight against lung cancer. 💰 A recent economic study showed potential U.S. healthcare savings of up to $1.27 billion annually if CyPath® Lung were integrated into standard care. 📄 https://lnkd.in/eA9CK8hV Titus Regional Medical Center Pulmonology Precision Pathology Laboratory Services U.S. Department of Veterans Affairs Breast Cancer Now #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #Investing

💰 Better Choice Company (NYSE:BTTR) Reinstates and Expands Stock Repurchase Program to $6.5M Better Choice is doubling down on shareholder value—its Board has reinstated the company’s buyback program and increased authorization to $6.5M through the end of 2025. 📈 Under the prior $5M program, Better Choice Company (NYSE:BTTR) repurchased 102,405 shares at an average price of $1.99. The move signals confidence in the company’s valuation and long-term prospects. 🔍 Why This Matters for Investors: • Undervalued Signal: Leadership sees current share price as below intrinsic value. • Flexible Capital Deployment: Repurchases to be funded from cash on hand. • Shareholder-Focused Strategy: Potential to enhance EPS and reduce share float. 📄 https://lnkd.in/ekwfCyBG ▼Pet Food Processing Veterinary Practice Biotechnology News #BTTR #ShareBuyback #StockRepurchase #PetWellness #InvestorUpdate #FinancialNews #EquityValue

🧬 Calidi Biotherapeutics (NYSE American: CLDI): FDA Greenlights IND for Novel Solid Tumor Therapy Calidi Biotherapeutics has received FDA clearance for its Investigational New Drug (IND) application for CLD-201—a first-in-class, allogeneic stem cell-based immunotherapy targeting solid tumors, including breast cancer, head & neck cancer, and soft tissue sarcoma. 💡 Why This Matters to Investors: - Clinical Advancement: This IND paves the way for first-in-human trials, marking a key milestone in Calidi Biotherapeutics' oncology pipeline. - Innovative Tech: CLD-201 combines stem cells with oncolytic vaccinia virus to evade immune inactivation and directly kill cancer cells. - Market Opportunity: Addresses major unmet needs in cancers with limited effective treatment options. 📄 https://lnkd.in/eTZEgsbf California Institute for Regenerative Medicine (CIRM) Northwestern University City of Hope The Lancet Group #BiotechStocks #CancerTreatment #SolidTumors #FDAApproval #ClinicalTrials #Immunotherapy #InvestorNews

💸 ConnectM Technology Solutions (Nasdaq: CNTM): Aggressive Debt Reduction Sharpens Financial Trajectory ConnectM Technology Solutions has retired another $9M in debt in April—bringing total debt eliminated since going public in July 2024 to $40M. Outstanding liabilities now sit under $8M, and the company expects to achieve positive stockholder equity by Q2 2025. 📈 Why This Matters to Investors: - 90% Reduction in annual interest expense enhances profitability outlook. - Strengthened balance sheet positions ConnectM Technology Solutions for strategic growth in the clean energy and tech space. - Financial flexibility could support future acquisitions, R&D, or expansion into new markets. 🔗 https://lnkd.in/ecUkGbPq GE Vernova's Electrification businesses Electrification Institute S&P Global Commodity Insights #CNTM #SmallCapStocks #DebtReduction #CleanTech #EnergyInnovation #Investing #FinancialNews #BalanceSheetStrength

📢 BullFrog AI (Nasdaq: BFRG) Investor Webinar on April 23 — Unlocking the Future of Drug Development with AI BullFrog AI's leadership invites investors to a live webinar on Wednesday, April 23 at 4:15 PM ET, showcasing how its proprietary bfLEAP® platform and BullFrog Data Networks® are reshaping the biotech landscape. 💡 Why This Matters to Investors: - Massive Market Need: With only ~12% of drugs reaching approval from Phase 1, BullFrog AI's AI-driven insights address a $200B+ R&D challenge. - Disruptive Technology: bfLEAP® reveals hidden patterns in high-dimensional datasets, improving target discovery and trial outcomes. - Dual Growth Strategy: Revenue-generating platform + drug asset development + prestigious partners (e.g., J. Craig Venter Institute). Don’t miss this opportunity to learn how BullFrog AI is helping biopharma companies do more with less—while tackling inefficiencies across the drug development pipeline. 🔗 https://lnkd.in/eVt344HH Lieber Institute for Brain Development Biotechnology Biotechnology News #BFRG #BiotechInvesting #AIinHealthcare #DrugDiscovery #InvestorWebinar #HealthcareAI

🚨 Aptevo Therapeutics (Nasdaq: APVO) Reports 90% Remission* in AML Trial In its RAINIER Phase 1b/2 trial, Aptevo Therapeutics Inc reported 9 out of 10 patients achieved remission when treated with mipletamig + venetoclax + azacitidine—a 90% remission rate, outperforming the ~66% rate typically seen with the doublet (venetoclax + azacitidine) alone. (*Remission = complete remission (CR) and, complete remission with blood markers that have not yet recovered (CRi). 💡 Why It Matters: • Consistent Efficacy – Mirrors results from prior Phase 1 (R/R AML) • High Unmet Need – AML treatments remain limited • Momentum Building – Cohort 2 enrollment is active; next data readout could be pivotal 🔗 Learn More: https://lnkd.in/eQpU7RTk Lymphoma, Leukemia & Myeloma Congress Biotechnology Biotechnology News #BiotechStocks #AML #ClinicalTrials #CancerResearch #Aptevo #APVO #Oncology

💰 Better Choice Company (NYSE:BTTR) Strengthens Balance Sheet with $8.1M Deal for Halo Asia Business Better Choice sold its Halo Asia operations to CZC Company LTD for $8.1 million in total proceeds, including $6.5 million in upfront cash—equivalent to $3.34 per share. The transaction also includes a 5-year royalty agreement with minimum revenue guarantees. 📦 Core Operations Remain: Better Choice retains full control of North American and non-Asia international operations, sharpening focus on its primary health & wellness markets. 💡 Why This Matters to Investors: 💵 Boosts liquidity with significant upfront cash 🔄 Adds recurring royalty income through 2029 🎯 Refocuses company strategy on high-growth core markets 🛠️ Unlocks flexibility for future capital deployment—potential buybacks, dividends, or diversification 🔗 https://lnkd.in/ed_EpvKM Mergers & Acquisitions (M&A) Veterinary Practice #BTTR #PetWellness #InvestorNews #ShareholderValue #AssetOptimization #PetIndustry

🤖 VSee Health (Nasdaq: VSEE) Introduces AI-Powered Telenursing Robotics to Cut Hospital Costs VSee has unveiled its new Telenursing Robotics solution, targeting a 3–5% reduction in hospital nursing expenses—a major line item accounting for ~60% of hospital operating costs. 💡 Why This Matters to Investors: - Cost Reduction & Efficiency: Hospitals could save millions annually, while improving patient satisfaction and throughput. - Strategic Pilots Underway: Clinical partnerships and research-driven pilots now launching with select hospitals to validate real-world ROI. - Massive Market Opportunity: Addresses a $787B digital health market with a scalable, AI-driven solution. 📄 https://lnkd.in/ep-vFe6C MedTech Dive Telemedicine #DigitalHealth #HealthcareInnovation #AI #Telenursing #HospitalEfficiency #MicroCapStocks #Investing #FinancialNews